Daniel Hyun, MD
Neurology · San Antonio, TXNPI 1194726448
Payments from drug & device makers
Across 1,966 payments — averaging $27.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$16K
- UCB, Inc.$8K
- Acadia Pharmaceuticals Inc$3K
- Teva Pharmaceuticals USA, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- Amgen$2K
- plus $20K from 54 others
What the payments were for
- Consulting fees$4,3708%
- Speaking & faculty fees$13,43125%
- Travel & lodging$1,0512%
- Food & beverage$34,18064%
- Education$1980%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,230 in reported general payments places this provider in the 80th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 193 | $1,038,329 |
| IngrezzaValbenazine Tosylate | 43 | $364,643 |
| RytaryCarbidopa/Levodopa | 235 | $289,931 |
| NourianzIstradefylline | 99 | $251,831 |
| EpidiolexCannabidiol (Cbd) | 25 | $218,278 |
| Nurtec OdtRimegepant Sulfate | 123 | $215,734 |
| XcopriCenobamate | 84 | $197,126 |
| Kesimpta PenOfatumumab | 17 | $171,719 |
| ApokynApomorphine Hcl | 13 | $157,916 |
| UbrelvyUbrogepant | 106 | $153,412 |
| BriviactBrivaracetam | 102 | $150,540 |
| RexultiBrexpiprazole | 65 | $99,055 |
| Aimovig AutoinjectorErenumab-Aooe | 104 | $94,973 |
| InbrijaLevodopa | 29 | $81,679 |
| AptiomEslicarbazepine Acetate | 22 | $50,957 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $2,576 | $1,038,329193 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $1,790 | $380,24963 claims |
| Amneal Pharmaceuticals LLCRytary | $1,196 | $289,931235 claims |
| Kyowa Kirin, Inc.Nourianz | $1,245 | $251,83199 claims |
| PfizerNurtec Odt, Zavzpret | $1,080 | $230,116136 claims |
| AbbVieUbrelvy, Qulipta, Botox | $16,044 | $204,009153 claims |
| SK Life Science, Inc.Xcopri | $882 | $197,12684 claims |
| UCB, Inc.Briviact, Nayzilam | $8,350 | $194,530156 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $305 | $99,05565 claims |
| Acorda Therapeutics, IncInbrija | $921 | $81,67929 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $748 | $50,95722 claims |
| MDD US Operations, LLCGocovri | $1,392 | $31,48819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,246 neurology providers in Texas.
Other neurology in San Antonio
- Ann BassSan Antonio$12.3M
- Juan Ramirez CastanedaSan Antonio$1.1M
- Eleni VaouSan Antonio$584K
- Rebecca RomeroSan Antonio$569K
- Kandasami SenthilkumarBeaumont$7.6M
- Bharathy SundaramSherman$7.2M
- Bhupesh DiheniaLubbock$6.9M
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.